Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 702

1.
2.

KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.

Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA.

Oncogene. 2007 Sep 27;26(44):6386-95. Epub 2007 Apr 23.

PMID:
17452978
3.

The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.

Sápi Z, Füle T, Hajdu M, Matolcsy A, Moskovszky L, Márk A, Sebestyén A, Bodoky G.

Diagn Mol Pathol. 2011 Mar;20(1):22-33. doi: 10.1097/PDM.0b013e3181eb931b.

PMID:
21326036
4.

Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: Immunohistochemical and mutational analyses.

Peterson MR, Piao Z, Weidner N, Yi ES.

Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):390-6.

PMID:
17122634
5.

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

Lasota J, Miettinen M.

Semin Diagn Pathol. 2006 May;23(2):91-102. Review.

PMID:
17193822
6.

Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.

Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, Oosterom AV, Hagemeijer A, Sciot R.

Mod Pathol. 2004 Aug;17(8):889-94.

7.

Interstitial cells of Cajal do not harbor c-kit or PDGFRA gene mutations in patients with sporadic gastrointestinal stromal tumors.

Nakajima T, Miwa S, Ando T, Fujinami H, Kajiura S, Hosokawa A, Takano Y, Sugiyama T.

J Gastroenterol. 2009;44(5):426-31. doi: 10.1007/s00535-009-0032-z. Epub 2009 Mar 31.

PMID:
19333543
8.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA.

Science. 2003 Jan 31;299(5607):708-10. Epub 2003 Jan 9.

9.

The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).

Du CY, Shi YQ, Zhou Y, Fu H, Zhao G.

J Surg Oncol. 2008 Sep 1;98(3):175-8. doi: 10.1002/jso.21104.

PMID:
18618605
10.

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Lasota J, Miettinen M.

Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28. Review.

PMID:
18312355
11.

Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.

Miettinen M, Sobin LH, Lasota J.

Am J Surg Pathol. 2009 Sep;33(9):1267-75. doi: 10.1097/PAS.0b013e3181a13e99.

PMID:
19440146
12.

High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.

Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, Vanderveer LA, Riddell D, Merkel E, Tarn C, Eisenberg BL, von Mehren M, Testa JR, Godwin AK.

Genes Chromosomes Cancer. 2009 Oct;48(10):886-96. doi: 10.1002/gcc.20689.

13.

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Zheng S, Chen LR, Wang HJ, Chen SZ.

Hepatogastroenterology. 2007 Dec;54(80):2285-90.

PMID:
18265649
14.

Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors.

Haller F, Happel N, Schulten HJ, von Heydebreck A, Schwager S, Armbrust T, Langer C, Gunawan B, Doenecke D, Füzesi L.

Mod Pathol. 2007 Oct;20(10):1103-11. Epub 2007 Aug 3.

15.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

16.

Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors.

Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Kim H, Hyung WJ, Noh SH, Kim JH, Yun CO, Liu ET, Kim H.

Oncogene. 2005 Feb 3;24(6):1066-74.

PMID:
15690055
17.

Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q.

Yamamoto H, Tobo T, Nakamori M, Imamura M, Kojima A, Oda Y, Nakamura N, Takahira T, Yao T, Tsuneyoshi M.

J Cancer Res Clin Oncol. 2009 Jun;135(6):791-8. doi: 10.1007/s00432-008-0514-z. Epub 2008 Nov 20.

PMID:
19020900
18.

Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.

Liegl B, Hornick JL, Corless CL, Fletcher CD.

Am J Surg Pathol. 2009 Mar;33(3):437-46. doi: 10.1097/PAS.0b013e318186b158.

PMID:
19011564
19.

Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.

Kang DY, Park CK, Choi JS, Jin SY, Kim HJ, Joo M, Kang MS, Moon WS, Yun KJ, Yu ES, Kang H, Kim KM.

Am J Surg Pathol. 2007 Feb;31(2):224-32.

PMID:
17255767
20.

Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.

Tzen CY, Wang MN, Mau BL.

Eur J Surg Oncol. 2008 May;34(5):563-8. Epub 2007 May 29.

PMID:
17532173
Items per page

Supplemental Content

Write to the Help Desk